Giuliana Ritorto

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini et al. · The Lancet Oncology · 2020 · 325 citations · Full text

Medicine, Oncology, Pharmacotherapy +8

Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial

Carlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio et al. · The Lancet Oncology · 2022 · 270 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

The Effects of Reiki Therapy on Pain and Anxiety in Patients Attending a Day Oncology and Infusion Services Unit

Nadia Birocco, Camilla Guillame, Silvana Storto et al. · American Journal of Hospice and Palliative Medicine® · 2011 · 86 citations

Medicine, Oncology, Oncology Nursing +17

Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study

Carlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio et al. · Journal of Clinical Oncology · 2024 · 50 citations

Medicine, Pharmacology, Gastrointestinal Oncology +1

Efficacy and Skin Toxicity Management with Cetuximab in Metastatic Colorectal Cancer: Outcomes from an Oncologic/Dermatologic Cooperation

Patrizia Racca, Laura Fanchini, Virginia Caliendo et al. · Clinical Colorectal Cancer · 2008 · 48 citations

Medicine, Dermatology, Oncology +16